Rybrevant shows colorectal cancer promise in latest bispecifics win - BioCentury

J&J's Rybrevant shows promise in colorectal cancer, with Phase II data suggesting it makes metastatic patients eligible for curative surgery, leading to a 49% ORR in the OrigAMI-1 study.